Not currently enrolling

Study of MT-401 in Patients With Acute Myeloid Leukemia after Stem Cell Transplant

The purpose of this study is to look at a new cell therapy, MT-401, and determine the best dose for treating AML. The study will also look at the safety, tolerability, and effectiveness of this new therapy.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Paul Armistead
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Blood Conditions
Cancer (Leukemia)
Transplant

IRB Number

21-2080

ClinicalTrials.gov

NCT04511130

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.